Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis
Authors:
- Richard AdamsRARichard Adams
- Kaitlyn GoeyKGKaitlyn Goey
- Benoist ChibaudelBCBenoist Chibaudel
- Miriam KoopmanMKMiriam Koopman
- Cornelis PuntCPCornelis Punt
- Dirk ArnoldDADirk Arnold
- Axel HinkeAHAxel Hinke
- Susanna Hegewisch-BeckerSHSusanna Hegewisch-Becker
- Aimery de GramontAGAimery de Gramont
- Roberto LabiancaRoberto Labianca
- Eduardo Diaz RubioEREduardo Diaz Rubio
- Kjell Magne TveitKTKjell Magne Tveit
- 1 September 2021
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 99, 102226
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK
This publication has 34 references indexed in Scilit:
- Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III ‘Stop and Go' Study Results - A Turkish Oncology Group TrialOncology, 2013
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII StudyJournal of Clinical Oncology, 2012
- First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyThe Oncologist, 2012
- PCN18 Intermittent Versus Continuous Chemotherapy for First-Line Treatment of Unresectable Metastatic Colorectal Cancer (CCRm): Systematic Review and Meta-AnalysisValue in Health, 2011
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet Oncology, 2011
- Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trialAnnals of Oncology, 2010
- Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 StudyJournal of Clinical Oncology, 2009
- OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR StudyJournal of Clinical Oncology, 2006
- Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trialThe Lancet, 2003
- Prognostic significance of thrombocytosis in patients with primary lung cancerEuropean Respiratory Journal, 1996